Completed PHASE1 INTERVENTIONAL 2-arm NCT01334879

High Dose Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy

High Dose (2.0mg) Intravitreal Ranibizumab for Recalcitrant Radiation Retinopathy

Sponsor: Genentech, Inc.

Updated 6 times since 2017 Last updated: Sep 30, 2014 Started: May 31, 2011 Primary completion: Nov 30, 2012 Completion: Nov 30, 2012

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01334879, this PHASE1 trial focuses on Radiation Retinopathy and remains completed. Sponsored by Genentech, Inc., it has been updated 6 times since 2011, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

6 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1
Feb 2017 — Jun 2018 [monthly]

Completed PHASE1

▶ Show 1 earlier version

Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

May 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Genentech, Inc.
The New York Eye Cancer Center

Data source: The New York Eye Cancer Center

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• New York, United States